Navaneel Kar Appointed as Director General of IPM India

Business by 2FIRSTS.ai

Jan.12.2024

Navaneel Kar Appointed as Director General of IPM India

Philip Morris International (PMI) has appointed Navaneel Kar as the Managing Director of its Indian subsidiary IPM India.

According to international media reports, Philip Morris International has appointed Navaneel Kar as the Managing Director of its Indian subsidiary, IPM India.

Prior to this, Karl served as the Sales President at Tata Consumer Products. He will report directly to Ankur Modi, the Cluster Head for South Asia and Indochina.

Carl has over 25 years of professional experience and has worked for renowned brands such as ITC and Tata Motors in India. He has successfully led teams and organizations in various categories and channels within the food, tobacco, personal care, and beverage sectors.

Indian Prime Minister Narendra Modi said in a statement, "I am pleased to welcome Navaneel Kaul as the Managing Director of IPM India. Kaul has demonstrated outstanding leadership and competence throughout his career. His entrepreneurial spirit and learning mindset will be crucial for propelling our Indian business into the next phase of growth.

Carl said: "I am thrilled to take on this new position at such an exciting moment and contribute to the company's growth and overall success. I am looking forward to working with the team, leveraging our competitive advantage, and simultaneously fostering an inclusive, diverse, and progressive work environment.

Also Read:

[1] Wade Huckabee Appointed Senior Vice President of BAT's Subsidiary

[2] Dzulkefly Ahmad Appointed as Malaysia's Health Minister Again

[3] Blinc Group Announces Leadership Changes, Pete Sahani Appointed CEO

#Traditional tobacco #Asia #India #Market #Products #Tobacco #Personnel appointment

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Alan Zhao: What Altria’s on! PLUS Authorization Really Signals About FDA PMTA Enforcement

In this in-depth commentary for 2Firsts, Alan Zhao examines what Altria’s on! PLUS authorization really signals about FDA PMTA enforcement. Beyond the headline approval, FDA’s language, process design and product choices offer rare insight into how nicotine pouch regulation is taking shape—and what it means for industry compliance, in one of the earliest expert reads of the decision.

Regulations

Dec.20 by 2Firsts Perspectives

Exclusive: Altria Confirms FDA Grants Marketing Authorization to on! PLUS, Ending More Than a Year of PMTA Review

Altria on December 19 confirmed that six on! PLUS nicotine pouch products had received U.S. FDA marketing authorization, ending a PMTA review lasting more than a year after the company moved ahead with launch plans before clearance.

Regulations

Dec.20

Lawmakers Push to Include E-Cigarettes in Vietnam’s Revised Investment Law Ban

Vietnam’s National Assembly has debated amendments to the Investment Law that would include e-cigarettes, heated tobacco, and nitrous oxide (N₂O) in the list of prohibited business activities. Lawmakers supported a total ban consistent with WHO recommendations and previous National Assembly resolutions, citing rising youth addiction rates. Finance Minister Nguyễn Văn Thắng confirmed that the ban would apply comprehensively, with a short transition period for foreign factories.

Nov.27 by 2FIRSTS.ai